NDAORALTABLET, EXTENDED RELEASE
Approved
Nov 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EFIDAC 24 is an extended-release oral tablet formulation of chlorpheniramine maleate, a first-generation antihistamine used to treat allergic conditions including urticaria, pruritus, and allergic rhinitis. The drug works by blocking histamine H1 receptors, providing sustained symptom relief over 24 hours.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%); team sizes are likely lean and focused on margin protection rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.
Started Jan 2015
53 enrolled
Common Cold
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
Started Sep 2012
310 enrolled
Eczema
Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents
Started Dec 2008
36 enrolled
Allergic Reactions
Career Relevance
Working on EFIDAC 24 offers experience in mature product lifecycle management, competitive strategy, and generic transition planning—skills valuable for portfolio roles. However, the approaching LOE and minimal linked job openings suggest limited growth trajectory and team contraction.
Worked on EFIDAC 24 CHLORPHENIRAMINE MALEATE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.